Ge, Mengqin
Man, Kenneth K.
Chui, Celine S.
Chan, Esther W.
Wong, Ian C.
Article History
First Online: 5 June 2019
Compliance with Ethical Standards
:
: This study was supported by Pfizer Corporation Hong Kong Limited [project tracking number: W1198308].
: The study protocol was approved by the Hospital Authority Hong Kong West Cluster and University of Hong Kong Institutional Review Board (UW14-602).
: Xue Li has received research funding from the Food and Health Bureau of the Government of Hong Kong. Kenneth Man received the CW Maplethorpe Fellowship and personal fees from IQVIA Holdings, Inc., unrelated to this work. Esther Chan has received research funding from Wellcome Trust, United Kingdom; National Natural Science Fund of China, China; The Hong Kong Research Grants Council; The Research Fund Secretariat of the Food and Health Bureau; Narcotics Division of the Security Bureau of The Government of the Hong Kong Special Administrative Region; and Bristol-Myers Squibb, Pfizer, Bayer and Janssen, a Division of Johnson & Johnson, for work unrelated to this study. Ian Wong has received grants from the Research Grants Council (RGC, Hong Kong), Innovative Medicines Initiative (IMI), Shire, Janssen-Cilag, Eli-Lily, Pfizer, Bayer, and the European Union FP7 program, outside the submitted work. Ian Wong is a member of the National Institute for Health and Clinical Excellence (NICE) ADHD Guideline Group, the British Association for Psychopharmacology ADHD guideline group, and advisor to Shire. Mengqin Ge and Celine Chui declare no conflict of interest.